Versican expression is an adverse prognostic factor in MLL-rearranged infant acute lymphoblastic leukaemia
- 1 April 2016
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 57, 87-90
Abstract
No abstract availableFunding Information
- KWF Kankerbestrijding
- Stichting Kinderen Kankervrij
This publication has 8 references indexed in Scilit:
- Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group studyBlood, 2012
- Gene expression profiling–based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infantsBlood, 2010
- Expression profiles of adult T-cell leukemia–lymphoma and associations with clinical responses to zidovudine and interferon αLeukemia & Lymphoma, 2010
- Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocolBlood, 2009
- A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trialThe Lancet, 2007
- Versican: a versatile extracellular matrix proteoglycan in cell biologyCurrent Opinion in Cell Biology, 2002
- Biological and therapeutic aspects of infant leukemiaBlood, 2000
- In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditionsBlood, 1990